PathWhiz

PathWhiz ID	Pathway	Meta Data
PW128518 View Pathway	drug action Cabozantinib Action Pathway Homo sapiens Cabozantinib is a tyrosine kinase inhibitor with broad applications in oncology. Originally approved in 2012 under the brand name Cometriq, it was primarily indicated for metastatic medullary thyroid cancer. Subsequently, a capsule formulation known as Cabometyx gained approval for the treatment of advanced renal cell carcinoma in 2016. In 2019, this same formulation received additional approvals for the treatment of hepatocellular carcinoma in patients who had previously been treated with sorafenib. Cabozantinib's mechanism of action involves inhibiting various receptor tyrosine kinases, effectively suppressing processes such as metastasis, angiogenesis, and oncogenesis, making it a versatile therapeutic option in the management of advanced cancers. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Dorsa Yahya Rayat Created On: September 01, 2023 at 12:22 Last Updated: September 01, 2023 at 12:22
PW146443 View Pathway	drug action Cabotegravir Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 18:12 Last Updated: October 07, 2023 at 18:12
PW127486 View Pathway	drug action Cabotegravir Action Pathway Homo sapiens Cabotegravir is an HIV-1 integrase inhibitor used for treatment and pre-exposure prophylaxis of HIV-1 infection. It is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine. Cabotegravir is transported into the infected cell then transported into the nucleus via importin nuclear transporter. The viral RNA is injected into the cell then transcribed into viral DNA via reverse transcriptase. It is then transported into the nucleus where it is integrated into the host DNA. Cabotegravir inhibits HIV integrase which prevents the viral DNA from being integrated into the host DNA. This prevents viral replication and further progression of the virus. It is used in combination with reverse transcriptase inhibitors which further prevents viral replication and progression of the virus. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: March 15, 2023 at 14:27 Last Updated: March 15, 2023 at 14:27
PW128274 View Pathway	drug action Cabergoline Mechanism of Action Action Pathway Homo sapiens Cabergoline stimulates centrally-located dopaminergic D2- and D3-receptors. Cabergoline is a long-acting agonist with a high affinity for D2 receptors. It also exhibits: weak agonist activity (in order of decreasing binding affinities) on 5-hydroxytryptamine (5-HT)2B, 5-HT2A, 5-HT1D, dopamine D4, 5-HT1A, dopamine D1, 5-HT1B and 5-HT2C receptors and antagonist activity on α2B, α2A, and α2C receptors. Cabergoline is probably more effective and causes fewer adverse effects than bromocriptine. However, it is much more expensive. Cabergoline is often used in patients who cannot tolerate the adverse effects of bromocriptine or in those who do not respond to bromocriptine. Cabergoline stops the brain from making and releasing the prolactin hormone from the anterior pituitary gland. The hypothalamic control of prolactin secretion is mostly inhibitory by prolactin inhibiting factor and dopamine is the main inhibitor that acts via type 2 dopamine (D2) receptor located on lactotrophs. Cabergoline is used in the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). It may also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: August 14, 2023 at 14:23 Last Updated: August 14, 2023 at 14:23
PW144377 View Pathway	drug action Cabergoline Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 13:31 Last Updated: October 07, 2023 at 13:31
PW145781 View Pathway	drug action Cabazitaxel Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:38 Last Updated: October 07, 2023 at 16:38
PW013303 View Pathway	metabolic C5-Branched Dibasic Acid Metabolism Arabidopsis thaliana A dibasic acid is an acid that has two hydrogen cations to donate to a base in an acid-base reaction . C5-branched dibasic acid metabolism takes place in the chloroplast stroma. Pyruvate from glycolysis is converted into (S)-2-Acetolactate by acetolactate synthase. A yet non-elucidated enzyme converts pyruvate into (R)-citramalate. The next two reactions are catalyzed by the same enzyme. First, isopropylmalate isomerase converts (R)-citramalate into citraconic acid and then it converts citraconic acid into D-erythro-3-methylmalate. Last, the reaction that converts D-erythro-3-methylmalate into 2-ketobutyric acid is catalyzed by the enzyme 3-isopropylmalate dehydrogenase. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Carin Li Created On: April 27, 2017 at 20:10 Last Updated: April 27, 2017 at 20:10
PW146353 View Pathway	drug action C11-12 isoparaffin Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 18:00 Last Updated: October 07, 2023 at 18:00
PW124296 View Pathway	signaling C.elegans aging Caenorhabditis elegans BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Guest: Anonymous Created On: October 30, 2020 at 13:34 Last Updated: October 30, 2020 at 13:34
PW064430 View Pathway	disease c-Met miRNA in T2DM associated HCC Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Guest: Anonymous Created On: December 02, 2017 at 04:23 Last Updated: December 02, 2017 at 04:23